Jed A. Barash
Research Subjects
Jed A. Barash has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alfred DeMaria
Massachusetts Department of Public Health Boston Massachusetts USA
2 shared publicationsAlfred Jr DeMaria
Massachusetts Department of Public Health, Jamaica Plain, MA
2 shared publicationsMegha Parikh
Massachusetts Department of Public Health Boston Massachusetts USA
2 shared publicationsMichael H. Lev
Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
2 shared publicationsRosa Ergas
Massachusetts Department of Public Health Boston Massachusetts USA
2 shared publicationsW. Andrew Kofke
Department of Anesthesiology and Critical Care University of Pennsylvania Philadelphia Pennsylvania USA
2 shared publications
Latest Publications
- 22 June 2026
- Published by Wiley in Hippocampus
- Vol. 36 (4) , e70111
Opioid‐Associated Hippocampal Injury: Past, Present, and Future Directions
Three of the great public health challenges of our time converge at the hippocampus. The first, dementia, most commonly in the form of Alzheimer's disease, is well known to cause progressive hippocampal damage, resulting in the memory loss associated with the illness. The second, COVID‐19 infection, has thus far been linked to hippocampal alterations across multiple studies. Lastly, the third, opioids—especially in the setting of misuse—have been associated with acute and persistent hippocampal injury; this review focuses on the collection of pre‐clinical, clinical, and epidemiologic observations supporting this final relationship. Basic science work dating back decades has demonstrated a hypermetabolic response to opioids and associated damage to the hippocampus. The earliest cases recognized as opioid‐associated amnestic syndrome (OAS) were subsequently identified in 2012 and reported as part of larger case series several years later. In 2019, a related but more fulminant syndrome involving cerebellar, hippocampal, and basal nuclei transient edema with restricted diffusion (CHANTER) was first described. From these investigations, a growing body of data has since emerged to suggest that regular opioid use, particularly at higher doses or potency, may be connected to a reduction in hippocampal volume and greater risk of dementia. This review begins with a synthesis of data supporting the underlying pathological mechanisms of opioid‐associated hippocampal injury (OAHI), then covers the clinical spectrum of this phenomenon. Lastly, we will close with implications of OAHI that warrant further study, including the future epidemiologic impact on related cognitive disorders in the wake of the opioid epidemic and potential therapeutic applications of opioid antagonism for mild cognitive impairment.
- 22 June 2026
- Published by Wiley in Hippocampus
- Vol. 36 (4) , e70111
Opioid‐Associated Hippocampal Injury: Past, Present, and Future Directions
Three of the great public health challenges of our time converge at the hippocampus. The first, dementia, most commonly in the form of Alzheimer's disease, is well known to cause progressive hippocampal damage, resulting in the memory loss associated with the illness. The second, COVID‐19 infection, has thus far been linked to hippocampal alterations across multiple studies. Lastly, the third, opioids—especially in the setting of misuse—have been associated with acute and persistent hippocampal injury; this review focuses on the collection of pre‐clinical, clinical, and epidemiologic observations supporting this final relationship. Basic science work dating back decades has demonstrated a hypermetabolic response to opioids and associated damage to the hippocampus. The earliest cases recognized as opioid‐associated amnestic syndrome (OAS) were subsequently identified in 2012 and reported as part of larger case series several years later. In 2019, a related but more fulminant syndrome involving cerebellar, hippocampal, and basal nuclei transient edema with restricted diffusion (CHANTER) was first described. From these investigations, a growing body of data has since emerged to suggest that regular opioid use, particularly at higher doses or potency, may be connected to a reduction in hippocampal volume and greater risk of dementia. This review begins with a synthesis of data supporting the underlying pathological mechanisms of opioid‐associated hippocampal injury (OAHI), then covers the clinical spectrum of this phenomenon. Lastly, we will close with implications of OAHI that warrant further study, including the future epidemiologic impact on related cognitive disorders in the wake of the opioid epidemic and potential therapeutic applications of opioid antagonism for mild cognitive impairment.
- Open Access
Surveillance for Opioid-Associated Amnestic Syndrome in Canada, 2010-2022
Objectives: A single diagnostic code could be used to perform surveillance for opioid-associated amnestic syndrome (OAS) in healthcare datasets on a national scale. Methods: A request was submitted to search the Discharge Abstract Database (DAD) and the National Ambulatory Care Reporting System (NACRS) in Canada for the ICD-10-CA code, F11.6 (mental and behavioural disorders due to use of opioids, amnesic syndrome) during fiscal years (FY) 2010-2011 through 2022-2023. The annual total of encounters using this code was determined and crude rates per million were calculated for the Canadian population represented. Results: National counts from DAD and NACRS combined ranged from <5 to 14 annually. Rates per million for available years fell between 0.17 and 0.48. For available data through FY 2015-2016, the mean number of annual combined encounters nationally was 6.3; for those years after, the mean was 10. The mean rate per million was 0.23 and 0.35 for these two periods, respectively. Discussion: This study represents the first effort to conduct surveillance for OAS on a national scale and suggests that the condition is relatively rare. Future efforts to validate the coded diagnosis of OAS with confirmed cases will help determine its value as a surveillance tool.
Open AccessSurveillance for Opioid-Associated Amnestic Syndrome in Canada, 2010-2022
Objectives: A single diagnostic code could be used to perform surveillance for opioid-associated amnestic syndrome (OAS) in healthcare datasets on a national scale. Methods: A request was submitted to search the Discharge Abstract Database (DAD) and the National Ambulatory Care Reporting System (NACRS) in Canada for the ICD-10-CA code, F11.6 (mental and behavioural disorders due to use of opioids, amnesic syndrome) during fiscal years (FY) 2010-2011 through 2022-2023. The annual total of encounters using this code was determined and crude rates per million were calculated for the Canadian population represented. Results: National counts from DAD and NACRS combined ranged from <5 to 14 annually. Rates per million for available years fell between 0.17 and 0.48. For available data through FY 2015-2016, the mean number of annual combined encounters nationally was 6.3; for those years after, the mean was 10. The mean rate per million was 0.23 and 0.35 for these two periods, respectively. Discussion: This study represents the first effort to conduct surveillance for OAS on a national scale and suggests that the condition is relatively rare. Future efforts to validate the coded diagnosis of OAS with confirmed cases will help determine its value as a surveillance tool.
- Open Access
- 13 November 2023
- Published by Wiley in European Journal of Neurology
- Vol. 31 (2)
Is there a relationship between opioid use and transient global amnesia?
Background and purpose: Opioid‐associated amnestic syndrome (OAS) and transient global amnesia (TGA) are conditions with clinical overlap. We therefore sought to determine whether opioid use might be associated with TGA.Methods: Data from the Massachusetts Department of Public Health Syndromic Surveillance program were queried to ascertain the frequency of opioid use among emergency department (ED) encounters for TGA compared to that for all other ED visits between January 2019 and June 2023.Results: A total of 13,188,630 ED visits were identified during the study period. Of 1417 visits for TGA, one visit met the exposure definition for opioid use. There were 13,187,213 visits for other indications, 57,638 of which were considered opioid‐exposed. The odds ratio for the relationship between opioid use and TGA was 0.16 (95% confidence interval 0.02, 1.14).Conclusion: Despite the clinical overlap between OAS and TGA, surveillance data from ED visits in Massachusetts do not suggest that opioid use is a risk factor for TGA, indicating that OAS and TGA are distinct entities.
- 13 November 2023
- Published by Wiley in European Journal of Neurology
- Vol. 31 (2)
Open AccessIs there a relationship between opioid use and transient global amnesia?
Background and purpose: Opioid‐associated amnestic syndrome (OAS) and transient global amnesia (TGA) are conditions with clinical overlap. We therefore sought to determine whether opioid use might be associated with TGA.Methods: Data from the Massachusetts Department of Public Health Syndromic Surveillance program were queried to ascertain the frequency of opioid use among emergency department (ED) encounters for TGA compared to that for all other ED visits between January 2019 and June 2023.Results: A total of 13,188,630 ED visits were identified during the study period. Of 1417 visits for TGA, one visit met the exposure definition for opioid use. There were 13,187,213 visits for other indications, 57,638 of which were considered opioid‐exposed. The odds ratio for the relationship between opioid use and TGA was 0.16 (95% confidence interval 0.02, 1.14).Conclusion: Despite the clinical overlap between OAS and TGA, surveillance data from ED visits in Massachusetts do not suggest that opioid use is a risk factor for TGA, indicating that OAS and TGA are distinct entities.
- 3 July 2023
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
- Vol. 36 (3) , 194-197
Longitudinal Imaging in a Patient With Opioid-associated Amnestic Syndrome
Since 2012, individuals with a history of opioid misuse have infrequently been observed to develop a sudden-onset amnestic syndrome associated with bilateral hippocampal-restricted diffusion on MRI. Follow-up imaging of this opioid-associated amnestic syndrome (OAS) has revealed persistent hippocampal abnormalities. Given these observations, as well as neuropathological studies demonstrating excessive tau deposition in the hippocampi and other brain regions of individuals with opioid misuse, we describe longitudinal imaging of a patient with a history of OAS from presentation through 53 months later, when tau positron emission tomography (PET) was performed. Our patient was a 21-year-old woman with a history of attention-deficit hyperactivity disorder and substance use disorder, including opioids (intravenous heroin), who was hospitalized for acute-onset, dense anterograde amnesia. Her urine toxicology screen was positive for opiates. On presentation, her brain MRI showed restricted diffusion as well as T2 and fluid-attenuated inversion recovery (FLAIR) hyperintensity of the hippocampi and globi pallidi. On day 3, magnetic resonance spectroscopy of a right hippocampal region of interest showed a mild reduction of N-acetyl aspartate/creatine, slight elevation of choline/creatine, and the appearance of lactate/lipid and glutamate/glutamine peaks. At 4.5 months, there was resolution of restricted diffusion on MRI, although a minimal anterior T2 and FLAIR hyperintense signal in the right hippocampus persisted. However, by 53 months, when mild memory loss was reported, the hippocampi appeared normal on MRI, and [18F]T807 (tau) PET showed no uptake suggestive of tau deposition. This case report supports the investigation into the hypothesis that OAS may follow a trajectory of reversible metabolic injury.
- 3 July 2023
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
- Vol. 36 (3) , 194-197
Longitudinal Imaging in a Patient With Opioid-associated Amnestic Syndrome
Since 2012, individuals with a history of opioid misuse have infrequently been observed to develop a sudden-onset amnestic syndrome associated with bilateral hippocampal-restricted diffusion on MRI. Follow-up imaging of this opioid-associated amnestic syndrome (OAS) has revealed persistent hippocampal abnormalities. Given these observations, as well as neuropathological studies demonstrating excessive tau deposition in the hippocampi and other brain regions of individuals with opioid misuse, we describe longitudinal imaging of a patient with a history of OAS from presentation through 53 months later, when tau positron emission tomography (PET) was performed. Our patient was a 21-year-old woman with a history of attention-deficit hyperactivity disorder and substance use disorder, including opioids (intravenous heroin), who was hospitalized for acute-onset, dense anterograde amnesia. Her urine toxicology screen was positive for opiates. On presentation, her brain MRI showed restricted diffusion as well as T2 and fluid-attenuated inversion recovery (FLAIR) hyperintensity of the hippocampi and globi pallidi. On day 3, magnetic resonance spectroscopy of a right hippocampal region of interest showed a mild reduction of N-acetyl aspartate/creatine, slight elevation of choline/creatine, and the appearance of lactate/lipid and glutamate/glutamine peaks. At 4.5 months, there was resolution of restricted diffusion on MRI, although a minimal anterior T2 and FLAIR hyperintense signal in the right hippocampus persisted. However, by 53 months, when mild memory loss was reported, the hippocampi appeared normal on MRI, and [18F]T807 (tau) PET showed no uptake suggestive of tau deposition. This case report supports the investigation into the hypothesis that OAS may follow a trajectory of reversible metabolic injury.
- 10 January 2023
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 36 (1) , 88-89
Amnesia as an Adverse Event Associated With Fentanyl: An Analysis of the US Food and Drug Administration Adverse Event Reporting System, 2011-2021
- 10 January 2023
- Published by Wolters Kluwer Health in Journal of Neurosurgical Anesthesiology
- Vol. 36 (1) , 88-89
Amnesia as an Adverse Event Associated With Fentanyl: An Analysis of the US Food and Drug Administration Adverse Event Reporting System, 2011-2021
- 9 June 2022
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 16 (6) , 684-688
Application of an Existing Syndromic Surveillance System to Quantify Possible Cases of Opioid-associated Amnestic Syndrome in Massachusetts
Objectives: In recent years, an opioid-associated amnestic syndrome (OAS) was identified in Massachusetts through elicited reporting by health care providers (traditional surveillance, TS). Whether OAS occurs more frequently and with a wider spatiotemporal distribution in Massachusetts remains unclear. We compared the frequency and spatiotemporal characteristics of emergency department (ED) visits for possible OAS (pOAS) using a pre-existing syndromic surveillance system (SyS) with OAS cases captured through TS. Methods: SyS was queried for Massachusetts ED visits in 15- to 55- year-olds with a chief complaint text and discharge codes for memory loss in association with codes for opioid use (pOAS). SyS data were extracted for 2016–2020, whereas TS was conducted for 2012–2018. Cases identified by SyS and TS were stratified by demographic and spatiotemporal variables. Results: TS ascertained 22 reported cases of OAS (18 males) between 2012 and 2018, ranging from 0 to 5 annually. No identified OAS patients presented between January and March or in western Massachusetts. Between 2016 and 2020, SyS identified 82 ED visits (49 males) with pOAS, ranging from 13 to 22 per year. Over the 5-year period, at least 2 ED visits for pOAS occurred during each month of the year (24 total during January, February, or March) and at least 1 visit occurred in each county except 2, with the second largest number (11) in Berkshire County (at the western border of Massachusetts), where no cases were ascertained through TS. Conclusions: Although OAS is a relatively rare condition, use of SyS in Massachusetts suggests a broader and more frequent spatiotemporal distribution than previously indicated from TS.
- 9 June 2022
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 16 (6) , 684-688
Application of an Existing Syndromic Surveillance System to Quantify Possible Cases of Opioid-associated Amnestic Syndrome in Massachusetts
Objectives: In recent years, an opioid-associated amnestic syndrome (OAS) was identified in Massachusetts through elicited reporting by health care providers (traditional surveillance, TS). Whether OAS occurs more frequently and with a wider spatiotemporal distribution in Massachusetts remains unclear. We compared the frequency and spatiotemporal characteristics of emergency department (ED) visits for possible OAS (pOAS) using a pre-existing syndromic surveillance system (SyS) with OAS cases captured through TS. Methods: SyS was queried for Massachusetts ED visits in 15- to 55- year-olds with a chief complaint text and discharge codes for memory loss in association with codes for opioid use (pOAS). SyS data were extracted for 2016–2020, whereas TS was conducted for 2012–2018. Cases identified by SyS and TS were stratified by demographic and spatiotemporal variables. Results: TS ascertained 22 reported cases of OAS (18 males) between 2012 and 2018, ranging from 0 to 5 annually. No identified OAS patients presented between January and March or in western Massachusetts. Between 2016 and 2020, SyS identified 82 ED visits (49 males) with pOAS, ranging from 13 to 22 per year. Over the 5-year period, at least 2 ED visits for pOAS occurred during each month of the year (24 total during January, February, or March) and at least 1 visit occurred in each county except 2, with the second largest number (11) in Berkshire County (at the western border of Massachusetts), where no cases were ascertained through TS. Conclusions: Although OAS is a relatively rare condition, use of SyS in Massachusetts suggests a broader and more frequent spatiotemporal distribution than previously indicated from TS.
- 1 November 2021
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 47 (4) , 270.1-270
Letter to the editor: in response to ‘association between widespread pain and dementia, Alzheimer’s disease and stroke: a cohort study from the Framingham Heart Study’
- 1 November 2021
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 47 (4) , 270.1-270
Letter to the editor: in response to ‘association between widespread pain and dementia, Alzheimer’s disease and stroke: a cohort study from the Framingham Heart Study’
- 1 October 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 417, 117048
Opioid-associated amnestic syndrome: Description of the syndrome and validation of a proposed definition
- 1 October 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 417, 117048
Opioid-associated amnestic syndrome: Description of the syndrome and validation of a proposed definition